Resistance to Proteasome Inhibitors in Cancer : Molecular Mechanisms and Strategies to Overcome Resistance - Dou, Q. Ping.; SpringerLink (Online service) (Cham : Springer International Publishing : Imprint: Springer, 2014)
Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer -- Resistance to proteasome inhibitors in multiple myeloma -- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma -- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis -- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy -- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition -- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies -- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches -- Targeting the proteasome pathway for the treatment of solid tumors -- Oxidative stress and the proteasome: mechanism and the therapeutic relevance -- Proteotoxic stress and proteasome inhibitor efficacy and resistance -- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy -- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2) -- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies -- Deubiquitinating enzymes as novel targets for cancer therapies.
Keywords: Cancer research; Drug resistance; Pharmacology; Molecular biology; Cancer Research; Drug Resistance; Pharmacology/Toxicology.; Molecular Medicine